Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

ASPP2 Attenuation Is an Early Step in Leukemogenesis Facilitating Acquisition of Mutations

Kerstin M Kampa-Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Charles Lopez, Marcus M Schittenhelm, Dr., MD

Blood (2014) 124 (21): 2221.

https://doi.org/10.1182/blood.V124.21.2221.2221

Published: 2014

Journal Articles

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Marcus M Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Julia Frey, Katja Schuster, PhD, Abhijit Ramachandran, Lothar Kanz, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2014) 124 (21): 2230.

https://doi.org/10.1182/blood.V124.21.2230.2230

Published: 2014

Journal Articles

Methylation Of The 5’UTR Of Apoptosis Stimulating Protein Of p53-2 (ASPP2) Impairs Gene Expression and Associates With Aggressive Disease and Therapy Failure In Acute Leukemia

Marcus M Schittenhelm, Dr., MD, Barbara Illing, Figen Akmut, Gunnar Blumenstock, Konstanze Döhner, MD, Charles D Lopez, MD, PhD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3770.

https://doi.org/10.1182/blood.V122.21.3770.3770

Published: 2013

Journal Articles

Identification Of C-Terminal Truncated Splice Variants Of The Apoptosis-Stimulating Protein Of p53-2 (ASPP2) In Acute Leukemia Lacking The p53-Binding Site

Kerstin M Kampa-Schittenhelm, Dr.,, Barbara Illing, Figen Akmut, Michael Walter, PhD, Charles D Lopez, MD, PhD, Marcus M Schittenhelm, Dr.,

Blood (2013) 122 (21): 1270.

https://doi.org/10.1182/blood.V122.21.1270.1270

Published: 2013

Journal Articles

Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By Combination Approaches

Kerstin M Kampa-Schittenhelm, Dr., MD, Figen Akmut, Barbara Illing, Marcus M Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3856.

https://doi.org/10.1182/blood.V122.21.3856.3856

Published: 2013

Journal Articles

Heatshockproteins-60 and 90 Are Overexpressed In Leukemia Stem Cells and Stabilize Oncogene Signaling

Kerstin M Kampa-Schittenhelm, Dr., MD, Tanja Grandl, Figen Akmut, Barbara Illing, Marcus M Schittenhelm, Dr., MD

Blood (2013) 122 (21): 3952.

https://doi.org/10.1182/blood.V122.21.3952.3952

Published: 2013

Journal Articles

Attenuation of Apoptosis-Stimulating Protein of p53 2 (ASPP2 or TP53BP2) Associates with High Risk Disease and Therapy Failure in Acute Leukemia

Marcus M Schittenhelm, Dr., MD, Charles D Lopez, MD, PhD, Lothar Kanz, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2012) 120 (21): 1416.

https://doi.org/10.1182/blood.V120.21.1416.1416

Published: 2012

Journal Articles

Heatshockprotein-60/90 Are Overexpressed in Leukemia Stem Cells and Stabilize Oncogene Signaling.

Kerstin M Kampa-Schittenhelm, Dr., MD, Lothar Kanz, MD, Marcus M Schittenhelm, Dr., MD

Blood (2012) 120 (21): 2472.

https://doi.org/10.1182/blood.V120.21.2472.2472

Published: 2012

Journal Articles

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Marcus M Schittenhelm, Dr., MD, Hartmut Doehner, MD, PhD, Konstanze Doehner, Lothar Kanz, MD, Michael C. Heinrich, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2012) 120 (21): 2474.

https://doi.org/10.1182/blood.V120.21.2474.2474

Published: 2012

Journal Articles

Identification of Three Tyrosine Phosphorylation Sites in the p53 Binding Domain of Apoptosis-Stimulating p53 Protein 2 (ASPP2) That Are Differentially Phosphorylated in Response to Chemotherapy in Patient Derived AML Blasts

Kerstin M Kampa-Schittenhelm, Dr., MD, Charles D Lopez, MD, PhD, Marcus M Schittenhelm, Dr., MD

Blood (2011) 118 (21): 1396.

https://doi.org/10.1182/blood.V118.21.1396.1396

Published: 2011

Journal Articles

The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia Models

Marcus Schittenhelm, Dr., MD, Tanja Grandl, Emmanuel Normant, PharmD, PhD, Helmut R. Salih, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2010) 116 (21): 3982.

https://doi.org/10.1182/blood.V116.21.3982.3982

Published: 2010

Journal Articles

AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms

Kerstin M Kampa-Schittenhelm, MD, Mohit Trikha, Richard F. Schlenk, MD, Hartmut Doehner, MD, Konstanze Doehner, MD, Michael C. Heinrich, MD, Marcus Schittenhelm, MD

Blood (2010) 116 (21): 291.

https://doi.org/10.1182/blood.V116.21.291.291

Published: 2010

Journal Articles

ASPP2 Expression In Acute Leukemia Modulates Response to Therapy

Kerstin M Kampa-Schittenhelm, Dr., MD, Charles D Lopez, Md, PhD, Marcus Schittenhelm, Dr., MD

Blood (2010) 116 (21): 3143.

https://doi.org/10.1182/blood.V116.21.3143.3143

Published: 2010

Journal Articles

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

Kerstin M Kampa, MD, Sandra Mueller, PhD, Katharina-Henriette Rasp, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 1740.

https://doi.org/10.1182/blood.V114.22.1740.1740

Published: 2009

Journal Articles

Insights Into the Role of ASPP2 (Apoptosis Stimulating Protein of p53-2) in Lymphomagenesis.

Kerstin M Kampa, MD, Sandra Mueller, PhD, Michael Bonin, PhD, Marcus M Schittenhelm, MD, Charles D Lopez, MD, PhD

Blood (2009) 114 (22): 1967.

https://doi.org/10.1182/blood.V114.22.1967.1967

Published: 2009

Journal Articles

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Kerstin M Kampa, MD, Tanja Grandl, Sandra Mueller, Emmanuel Normant, PhD, Michael Walter, PhD, Wolfgang Schuetz, PhD, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 2753.

https://doi.org/10.1182/blood.V114.22.2753.2753

Published: 2009

Journal Articles

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Sharon Shiraga, Lothar Kanz, MD, PhD, Michael C. Heinrich, MD, PhD

Blood (2007) 110 (11): 2370.

https://doi.org/10.1182/blood.V110.11.2370.2370

Published: 2007

Journal Articles

Apoptosis Stimulating Protein of p53 (ASPP2) Haploinsufficiency Promotes Irradiation-Induced High Grade Lymphomas in a Mouse Model.

Kerstin M. Kampa, MD, Jared D. Akoba, MD, Dexi Chen, MD, PhD, Kelly Beemer, MS, Joel Gay, Zhiyi Zhu, MS, Emerson Padiernos, BS, Christopher Corless, MD, PhD, Alexis Baily, William H. Flemming, MD, PhD, Charles D. Lopez, MD, PhD.

Blood (2007) 110 (11): 2639.

https://doi.org/10.1182/blood.V110.11.2639.2639

Published: 2007

Journal Articles

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Kevin W.H. Yee, MD, Lothar Kanz, MD,PhD, Michael C. Heinrich, MD,PhD

Blood (2007) 110 (11): 4213.

https://doi.org/10.1182/blood.V110.11.4213.4213

Published: 2007

Journal Articles

Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.

Marcus M. Schittenhelm, MD, Kevin W. Yee, M.D., Kerstin M. Kampa, M.D., Michael C. Heinrich, M.D.

Blood (2006) 108 (11): 1374.

https://doi.org/10.1182/blood.V108.11.1374.1374

Published: 2006

NARROW

ASPP2 Attenuation Is an Early Step in Leukemogenesis Facilitating Acquisition of Mutations

Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL)

Methylation Of The 5’UTR Of Apoptosis Stimulating Protein Of p53-2 (ASPP2) Impairs Gene Expression and Associates With Aggressive Disease and Therapy Failure In Acute Leukemia

Identification Of C-Terminal Truncated Splice Variants Of The Apoptosis-Stimulating Protein Of p53-2 (ASPP2) In Acute Leukemia Lacking The p53-Binding Site

Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By Combination Approaches

Heatshockproteins-60 and 90 Are Overexpressed In Leukemia Stem Cells and Stabilize Oncogene Signaling

Attenuation of Apoptosis-Stimulating Protein of p53 2 (ASPP2 or TP53BP2) Associates with High Risk Disease and Therapy Failure in Acute Leukemia

Heatshockprotein-60/90 Are Overexpressed in Leukemia Stem Cells and Stabilize Oncogene Signaling.

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Identification of Three Tyrosine Phosphorylation Sites in the p53 Binding Domain of Apoptosis-Stimulating p53 Protein 2 (ASPP2) That Are Differentially Phosphorylated in Response to Chemotherapy in Patient Derived AML Blasts

The Heatshockprotein-90 Inhibitor IPI-504 Potently Overcomes Tyrosinekinase Inhibitor-Induced Activation of Cell Protection Mechanisms and Degrades HSP-Client Proteins KIT and FLT3 In Acute Leukemia Models

AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms

ASPP2 Expression In Acute Leukemia Modulates Response to Therapy

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

Insights Into the Role of ASPP2 (Apoptosis Stimulating Protein of p53-2) in Lymphomagenesis.

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

Apoptosis Stimulating Protein of p53 (ASPP2) Haploinsufficiency Promotes Irradiation-Induced High Grade Lymphomas in a Mouse Model.

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only